“…Although it is reported to be associated with acquired immune deficiency syndrome, Epstein-Barr virus infection, Hodgkin’s lymphoma, immunosuppression after organ transplantation, and hepatitis C virus-related liver cirrhosis, the precise steps leading to leiomyosarcoma have not been fully identified. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States, although nonalcoholic steatohepatitis (NASH) is on the rise. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…OBJECTIVE: Regional disparities were observed in the outcomes of interferon (IFN)-based therapy for chronic hepatitis C virus (HCV) infection in a Japanese nationwide study. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…It also correlated with overall mortality in patients with hepatitis C virus (HCV) related decompensated cirrhosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Aab targeting these relatively unknown structures have been almost exclusively observed in hepatitis C virus (HCV) patients who have undergone treatment with pegylated interferon-a/ribavirin (IFN/RBV) therapy. …”
Enlace del recurso
Enlace del recurso

“…The assay was also successfully adapted to detect RNA polymerization activity by different RdRps, illustrated here using purified RdRps from hepatitis C virus and foot-and-mouth disease virus. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Exhaustion of cytotoxic effector natural killer (NK) and CD8(+) T cells have important functions in the establishment of persistent viral infections, but how exhaustion is induced during chronic hepatitis C virus (HCV) infection remains poorly defined. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Reasons for ineligibility included: no prior platinum doublet treatment (23.6%), lack of tissue availability (22.7%), Eastern Cooperative Oncology Group performance status > 1 (14.1%), steroid use (18.2%), active cerebral nervous system metastasis (8.3%), hepatitis B/hepatitis C/human immunodeficiency virus (8.0%), and no measurable lesion (7.3%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Hepatocellular carcinoma (HCC) is a major health concern in Egypt owing to the high prevalence of hepatitis C virus (HCV) infection. HCC incidence is characterized by obvious male predominance, yet the molecular mechanisms behind this gender bias are still unidentified. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Overall prevalence of HIV virus was 21.1%, Hepatitis C 34.3% and Hepatitis B 3.2% in drug users. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: The effectiveness of sofosbuvir/ribavirin (SOF/RBV) combination therapy, which is one of the 1(st)-choice therapeutic options for patients with hepatitis C virus (HCV) genotype 2 (HCV-G2) in Japan according to the most recent version of the Japan Society of Hepatology guideline, for patients who experienced failure of the ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r+RBV) combination therapy, which was another option for patients with HCV-G2, is unknown. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The introduction of blood donor screening by virus nucleic acid amplification technology (NAT) in the mid to late 1990s was driven by the so-called AIDS and hepatitis C virus (HCV) epidemic, with thousands of recipients of infected blood products and components. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Background: Surgeons are at high risk of contracting infectious viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) through exposure to patients’ blood. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: No data are available on liver transplantation (LT) outcome and donor liver steatosis, classified as large droplet macrovesicular (Ld-MaS), small-droplet macrovesicular (Sd-MaS), and true microvesicular (MiS), taking into account the recipient Hepatitis C virus (HCV) status. AIM: We investigate the impact of allograft steatosis reclassified according to the Brunt classification on early graft function and survival after LT. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We previously demonstrated an immune-modulatory capacity by Notch signaling inactivation to reverse Tregs–Th17 disequilibrium in chronic hepatitis C. Thus, the aim of current study was to assess the role of Notch signaling in modulation Tregs and Th17 cells function in gastric cancer (GC) patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Despite the undeniable significance of blood transfusion in saving a millions life in emergencies and medical treatment, the quality of blood faced challenges from transfusion-transmitted infections (TTIs) such as HIV (human immunodeficiency virus), HBV (hepatitis B virus) and HCV (hepatitis C virus). This cross-sectional study was undertaken with the aim of determining the seroprevalence and risk factors of HIV, HBV, and HCV among blood donors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RACK1 is essential for the translation of many viruses including hepatitis C (HCV), polio, Drosophila C (DCV), Dengue, Cricket Paralysis (CrpV), and vaccinia viruses. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Ukraine has some of the highest rates of HIV and Hepatitis C (HCV) in Europe. Whether and how the current conflict, and its consequences, will lead to changes in the HIV and HCV epidemic in Ukraine is unclear. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…On stratified Cox regression analysis, propranolol also reduced the mortality risk in HCC patients with hepatitis B (HR = 0.92, 95% CI 0.85–0.99, P = 0.045), hepatitis C (HR = 0.85, 95% CI = 0.78–0.92, P = 0.001), liver cirrhosis (HR = 0.78, 95% CI = 0.72–0.85, P <0.001), and diabetes mellitus (HR = 0.87, 95% CI = 0.81–0.94, P = 0.008). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso